Annexon, Inc.

ANNXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1528115

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$113.8M	$112.5M	$100.1M	$49.3M	$24.5M
Operating Expenses	$143.7M	$145.6M	$130.7M	$63.5M	$32.5M
Operating Income (Loss)	-$143.7M	-$145.6M	-$130.7M	-$63.5M	-$32.5M
Other Nonoperating Income (Expense)	—	—	—	—	$1.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$134.2M	$141.9M	$130.3M	-$63.4M	—
Income Tax Expense (Benefit)	$0.00	$0.00	—	—	$4.0K
Net Income (Loss) Attributable to Parent	-$134.2M	-$141.9M	-$130.3M	-$63.4M	-$37.2M
Earnings Per Share, Basic	-$1.77	-$2.60	-$3.40	—	—
Earnings Per Share, Diluted	-$1.77	-$2.60	-$3.40	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$297.7M	$285.1M	$287.0M	$355.9M	$49.9M
Assets, Current	$263.9M	$248.1M	$247.7M	$354.0M	$45.4M
Cash and Cash Equivalents, at Carrying Value	$225.1M	$140.0M	$74.8M	$268.6M	$44.2M
Liabilities	$47.1M	$53.9M	$55.1M	$11.7M	$6.4M
Liabilities, Current	$17.9M	$22.4M	$21.7M	$10.6M	$4.9M
Accounts Payable, Current	$5.5M	$7.4M	$11.2M	$3.7M	$2.4M
Stockholders' Equity Attributable to Parent	$231.2M	$231.9M	$344.3M	-$100.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$121.1M	-$116.3M	-$106.1M	-$53.1M	-$28.4M
Net Cash Provided by (Used in) Investing Activities	$70.7M	$58.4M	-$88.2M	-$83.2M	-$267.0K
Net Cash Provided by (Used in) Financing Activities	$135.5M	$122.9M	$1.8M	$360.9M	$28.4M
Payments to Acquire Property, Plant, and Equipment	$193.0K	$6.5M	$1.7M	$464.0K	$267.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)